Future Possibilities for CAR T Cells in Non-Hodgkin's Lymphoma

Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin’s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin’s lymphoma.

Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin’s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin’s lymphoma, and physicians will have options when treating their patients.

In 2017, a new CAR T-cell therapy, axicabtagene ciloleucel (Yescarta), was approved by the FDA for the treatment of patients with non-Hodgkin’s lymphoma. Based on results from the JULIET and TRANSCEND trials, Perales expects that 2 new CAR T-cell agents may also be approved in 2018.